What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cognition
- Psychiatry
His primary areas of study are Nicotine, Nicotinic agonist, Neuroscience, Cognition and Internal medicine.
His studies in Nicotinic agonist integrate themes in fields like Anesthesia, Stimulation and Disease.
His Neuroscience study incorporates themes from Alzheimer's disease and Physical medicine and rehabilitation.
His Cognition research includes themes of Parkinson's disease and Attention deficit hyperactivity disorder.
The concepts of his Internal medicine study are interwoven with issues in Placebo, Endocrinology and Psychiatry.
His Endocrinology research is multidisciplinary, relying on both Anxiety, Dementia and Mood.
His most cited work include:
- Clock drawing in Alzheimer's disease. A novel measure of dementia severity. (814 citations)
- Effects of nicotinic stimulation on cognitive performance (360 citations)
- Intravenous nicotine in Alzheimer's disease: a pilot study (284 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Cognition, Internal medicine, Neuroscience, Clinical psychology and Endocrinology.
His research integrates issues of Menopause, Disease and Mood in his study of Cognition.
His research in Internal medicine intersects with topics in Placebo and Depression.
He has researched Neuroscience in several fields, including Alzheimer's disease, Muscarinic acetylcholine receptor and Nicotinic agonist.
He has included themes like Stimulation, Pharmacology and Nicotine in his Nicotinic agonist study.
His Endocrinology research incorporates themes from Anticholinergic and Anxiety.
He most often published in these fields:
- Cognition (51.23%)
- Internal medicine (35.66%)
- Neuroscience (29.10%)
What were the highlights of his more recent work (between 2017-2021)?
- Cognition (51.23%)
- Neuroscience (29.10%)
- Cognitive decline (14.75%)
In recent papers he was focusing on the following fields of study:
Paul A. Newhouse mostly deals with Cognition, Neuroscience, Cognitive decline, Clinical psychology and Effects of sleep deprivation on cognitive performance.
Paul A. Newhouse combines subjects such as Placebo, Internal medicine, Menopause, Disease and Neuroimaging with his study of Cognition.
His Internal medicine research is multidisciplinary, incorporating elements of Oncology and Cardiology.
His study in the fields of Basal forebrain and Cholinergic under the domain of Neuroscience overlaps with other disciplines such as In vivo.
The Cognitive decline study combines topics in areas such as Postmenopausal women, Estrogen and Neuropsychology.
His research in Mood focuses on subjects like Late life depression, which are connected to Nicotine.
Between 2017 and 2021, his most popular works were:
- Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19. (30 citations)
- Beyond Smoking Cessation: Investigating Medicinal Nicotine to Prevent and Treat COVID-19. (30 citations)
- Links between temporal acuity and multisensory integration across life span. (27 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cognition
- Major depressive disorder
Cognition, Neuroscience, Nicotinic agonist, Major depressive disorder and Nicotine are his primary areas of study.
His Cognition research is multidisciplinary, incorporating perspectives in Audiology and Internal medicine, Menopause, Disease, Estrogen.
His study on Disease also encompasses disciplines like
- Schizophrenia which connect with Mood,
- Pathological and related Cognitive decline.
His biological study spans a wide range of topics, including Glutamate receptor, Dysfunctional family and MEDLINE.
His Nicotinic agonist research incorporates elements of Clinical trial, Oncology, Quality of life, Ovarian cancer and Breast cancer.
His Nicotine study combines topics in areas such as Immunology and Pneumonia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
